Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s1054-3589(08)60233-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fear of falling impairs spatiotemporal gait parameters, mobility, and quality of life in Parkinson's disease: a cross-sectional study.
Neurol Sci
January 2025
Research Unit of Neurology, Neurophysiology, Neurobiology and Psychiatry, Department of Medicine and Surgery, Università Campus Bio-Medico Di Roma, Rome, Italy.
Background: Fear of Falling (FOF) significantly affects Parkinson's Disease (PD) patients by limiting daily activities and reducing quality of life (QoL). Though common in PD, the relation between FOF, mobility, and QoL remains unclear. This study examines the connections between FOF, gait, daily motor activity, and QoL in PD patients.
View Article and Find Full Text PDFComparison of Efficacy and Safety of Device-Based Interventions Versus Pharmacological Therapy in the Management of Patients With Advanced Parkinson's Disease: A Literature Review.
Cureus
December 2024
College of Medicine, Almaarefa University, Riyadh, SAU.
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by motor and non-motor symptoms that profoundly impact patients' quality of life. While pharmacological therapies such as levodopa remain the mainstay of treatment, their long-term use is often limited by motor complications. Device-based interventions, including deep brain stimulation (DBS) and continuous dopaminergic infusions, have emerged as alternatives, promising sustained symptomatic control and reduced medication-related side effects.
View Article and Find Full Text PDFDrug-induced Parkinson-like events: a real-world study from 2004 to the first quarter of 2024 based on FAERS.
Front Pharmacol
January 2025
Department of Pharmacy, The Affiliated Hospital, Southwest Medical University, Luzhou, China.
Background: Timely identification of drug-induced Parkinson-like events is essential to improve clinical management and enhance patients' quality of life. However, there is a significant lack of studies addressing these events in real-world settings.
Methods: To bridge this gap, we analyzed adverse event (AE) reports related to Parkinson-like events from the FDA Adverse Event Reporting System (FAERS) database from the first quarter of 2004 to the first quarter of 2024.
In the later stages of Parkinson's disease (PD), patients often manifest levodopa-induced dyskinesia (LID), compromising their quality of life. The pathophysiology underlying LID is poorly understood, and treatment options are limited. To move toward filling this treatment gap, the intrinsic and synaptic changes in striatal spiny projection neurons (SPNs) triggered by the sustained elevation of dopamine (DA) during dyskinesia were characterized using electrophysiological, pharmacological, molecular and behavioral approaches.
View Article and Find Full Text PDFextract ameliorates motor dysfunc-tion in mouse Parkinsons disease model through inhibiting neuronal apoptosis.
Zhejiang Da Xue Xue Bao Yi Xue Ban
January 2025
School of Medicine, Hangzhou City University, Zhejiang Provincial Key Laboratory of Novel Targets and Drug Study for Neural Repair, Hangzhou 310015, China.
Objectives: To investigate the protective effects and underlying mechanisms of extract on motor dysfunction in mouse model of Parkinson's disease (PD).
Methods: Eighty C57BL/6 male mice were randomly divided into five groups: control group, PD model group, levodopa treatment group (positive control group), low-dose GP treatment group (LD-GP group), and high-dose GP treatment group (HD-GP group), with 16 mice per group. The PD model was induced by injection of 6-hydroxydopamine into the substantia nigra pars reticulata in mice of last 5 groups.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!